<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F1F173A3-B507-4D5D-92FE-D0436BEF5657"><gtr:id>F1F173A3-B507-4D5D-92FE-D0436BEF5657</gtr:id><gtr:firstName>Victoria</gtr:firstName><gtr:surname>Salem</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701371"><gtr:id>2DAF1411-51C2-45CF-BA11-4ACDAC880663</gtr:id><gtr:title>Pathways of action of the potent anorexigenic gut hormones pancreatic polypeptide and peptide YY.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701371</gtr:grantReference><gtr:abstractText>Obesity is the major cause of early death in the UK, accounting for an estimated 600 premature
deaths per week. As yet there are no effective treatments and the factors which regulate appetite
and body weight are largely unknown.

Pancreatic polypeptide (PP) and Peptide YY (PYY) are hormones released from the gut in
response to food intake. Recently they have both been shown to act in the brain to reduce
appetite, and can therefore be thought of as part of the body?s mechanism of feeling full after a
meal. Infusions of these hormones into humans have consistently shown powerful and sustained
effects in lowering food intake. Exciting work is already underway to develop analogues that can
be effectively administered as weight-loss drugs.

There remains a large gap in our understanding of how PP and PYY exert their appetite-reducing
effects in the brain. Although their structure and effects are very similar, we know that they each
have a strong preference for different receptors and therefore stimulate different appetite signals in
the brain. By comparing and contrasting the effects of PP and PYY, I will contribute to our overall
understanding of the pathways that control of food intake.</gtr:abstractText><gtr:technicalSummary>Pancreatic polypeptide (PP) and peptide YY 3-36 (PYY3-36) potently inhibit food intake and may
be the basis for anti-obesity therapies. Although both are members of the NPY family of peptides,
they mediate their effects via different receptor systems and their effects on food intake are
additive. Initial findings suggested that the anorexigenic effects of PYY3-36 were mediated
exclusively in the arcuate nucleus whilst those of PP were via the area postrema in the brainstem.
However, new evidence shows that this is an over-simplistic model. The actual neuronal targets of
PP and PYY3-36 are unknown. I will therefore:
1) Identify the phenotype and location of neurones activated in response to PP and PYY3-36.
2) Determine the brain regions which mediate the anorexigenic effects of PP and PYY3-36.
3) Identify which are the most important neurones mediating the anorectic effects of PP and
PYY3-36.
Understanding this system will allow development of more effective agents to moderate appetite.</gtr:technicalSummary><gtr:fund><gtr:end>2013-12-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-06</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>219436</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>GSK Clinical Imaging Centre  (CIC)</gtr:department><gtr:description>Collaboration between Imperial College Division Diabetes, Endocrinology and Metabolism with GlaxoSmithKline Clinical Imaging Centre</gtr:description><gtr:id>986E4BF3-EEA1-42DF-8355-0E2D238101D4</gtr:id><gtr:impact>Cell Metabolism paper - fMRI findings in humans following co-administration of gut hormones. More papers in progress. Acquisition of MRI image analysis skills for use in future projects.</gtr:impact><gtr:outcomeId>YwAJBhQzqF7-1</gtr:outcomeId><gtr:partnerContribution>Access to human functional MRI scanning hardware, radiographers and help with image analysis</gtr:partnerContribution><gtr:piContribution>Project conception, design, ethics, recruitment, human infusion of gut hormones whilst scanning, help with image analysis. Collaborators provided imaging hardware and analysis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Numerous press releases</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>1E3C7B4D-D906-4742-8147-22153520EB1D</gtr:id><gtr:impact>http://www.dailymail.co.uk/health/article-2053804/How-diet-pill-using-gut-hormones-fool-brains-thinking-full.html?ito=feeds-newsxml
 
http://www.121doc.co.uk/news/gut-instinct-to-push-through-obesity-treatment-6618.html
 
http://www.medicalnewstoday.com/articles/236596.php
 
http://www.sciencecodex.com/read/simple_gut_hormone_combo_makes_our_brains_think_were_full-80343
 
http://www.science20.com/science_20/pyy_and_glp1_gut_hormones_trick_your_brain_feeling_full-83947
 
http://www.guardian.co.uk/science/2011/sep/11/obesity-food-appetite-suppressant
 
 
http://health-nutrition-fitness.net/weight-loss/obesity-pill-could-fool-brain-to-eat-less/
 
http://inventorspot.com/articles/do_obese_persons_have_guts_lose_weight
 
http://www.eurekalert.org/pub_releases/2011-10/cp-sgh102511.php
 
http://au.ibtimes.com/articles/237653/20111026/gut-feeling-hungry-imperial-college-london-glaxosmithkline-waljit-dhilio-appetite.htm
 
http://www.dnaindia.com/health/report_soon-hormone-inspired-pill-to-make-our-brains-think-were-full_1603749
 
http://www.medindia.net/news/Simple-Gut-Hormone-Inspired-Pill-for-Effective-Weight-loss-Study-92508-1.htm
 
http://truthdive.com/2011/10/26/Soon-hormone-inspired-pill-to-make-our-brains-think-we-re-full.html
 
http://news.bioscholar.com/2011/10/soon-hormone-inspired-pill-to-make-our-brains-think-we%E2%80%99re-full.html
 
http://www.fiercebiotechresearch.com/story/new-obesity-drugs-will-tell-brain-enough-enough/2011-09-12
 
http://www.bioportfolio.com/news/article/796715/New-Obesity-Drugs-Will-Tell-The-Brain-That-Enough-Is-Enough.html
 
http://www.onlineclinic.net/news/new-appetite-supressant-828.html
 
http://fattyblast.com/1939/obesity/new-obesity-drugs-will-tell-the-brain-that-enough-is-enough.php
 
http://www.pharmafeed.com/new-obesity-drugs-will-tell-the-brain-that-enough-is-enough
 
http://medicalxpress.com/news/2011-10-simple-gut-hormone-combo-brains.html
 
http://www.medicalnewstoday.com/articles/236596.php
 
http://www.co-operative.coop/magazine/in-the-news/food-drink/study-says-pill-could-help-cut-desire-for-fast-food/?articleid=003976#Comment

Numerous web-based discussions and queries.</gtr:impact><gtr:outcomeId>XvwEfDzjYPu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>3891F95C-CB98-45E5-91C3-9E779EC28892</gtr:id><gtr:title>The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e65e5fbd4d56aa838004e7af17e3d933"><gtr:id>e65e5fbd4d56aa838004e7af17e3d933</gtr:id><gtr:otherNames>De Silva A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn><gtr:outcomeId>Ad9uCskkxnj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45D3A435-6583-431D-BF87-60B79F859C28</gtr:id><gtr:title>Dexamethasone-suppressed corticotrophin-releasing hormone-stimulation test does not reliably diagnose or predict recurrence of Cushing disease.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aba5e0803783d9e5b722df0e592823bf"><gtr:id>aba5e0803783d9e5b722df0e592823bf</gtr:id><gtr:otherNames>Salem V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn><gtr:outcomeId>GC32rtbzFtt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2730700A-5459-4947-ACB3-64E44EF3464C</gtr:id><gtr:title>Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia.</gtr:title><gtr:parentPublicationTitle>Diabetes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b506e62dbe7269359b599b222c300632"><gtr:id>b506e62dbe7269359b599b222c300632</gtr:id><gtr:otherNames>Tan TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0012-1797</gtr:issn><gtr:outcomeId>pm_12485_25_23248172</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE7B95ED-6176-4333-9634-EA1115C5B2AD</gtr:id><gtr:title>Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b506e62dbe7269359b599b222c300632"><gtr:id>b506e62dbe7269359b599b222c300632</gtr:id><gtr:otherNames>Tan TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>54539f13819328.38182190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E60C33AB-EFBF-4A3F-A123-BC8FEABC7623</gtr:id><gtr:title>Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb1c44569bc5080866c5582768511724"><gtr:id>cb1c44569bc5080866c5582768511724</gtr:id><gtr:otherNames>Jayasena CN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn><gtr:outcomeId>C205C971BC6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0713A94-A3B3-414A-A84B-88F0E35217AD</gtr:id><gtr:title>Familial adenomatous polyposis and hypertension.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17fabfb19208baac057b6f39cfa62200"><gtr:id>17fabfb19208baac057b6f39cfa62200</gtr:id><gtr:otherNames>Hopkins TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>acVMtGfcrGP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D9E416A-AD15-4CB4-93A7-451D35193FB1</gtr:id><gtr:title>Approaches to the pharmacological treatment of&amp;nbsp;obesity.</gtr:title><gtr:parentPublicationTitle>Expert review of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aba5e0803783d9e5b722df0e592823bf"><gtr:id>aba5e0803783d9e5b722df0e592823bf</gtr:id><gtr:otherNames>Salem V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1751-2433</gtr:issn><gtr:outcomeId>XeQZCASQ1GM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F797E024-5FE8-48BE-8D34-B67D2423B8D2</gtr:id><gtr:title>Rimonabant: From RIO to Ban.</gtr:title><gtr:parentPublicationTitle>Journal of obesity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f17e0eb55551fe287eb8ce77c9aebbd"><gtr:id>9f17e0eb55551fe287eb8ce77c9aebbd</gtr:id><gtr:otherNames>Sam AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2090-0708</gtr:issn><gtr:outcomeId>Nwfb3YR8ecL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DB9D5C4-CFC1-429E-B075-B606558A64DF</gtr:id><gtr:title>Paraneoplastic hypoglycemia-&amp;quot;big&amp;quot; deal.</gtr:title><gtr:parentPublicationTitle>Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f17e0eb55551fe287eb8ce77c9aebbd"><gtr:id>9f17e0eb55551fe287eb8ce77c9aebbd</gtr:id><gtr:otherNames>Sam AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1530-891X</gtr:issn><gtr:outcomeId>RkiuCwZ5nMu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22BE697C-831F-4622-B6F9-6A314CB49B0E</gtr:id><gtr:title>Gastrointestinal satiety signals.</gtr:title><gtr:parentPublicationTitle>Annual review of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8b607e59f237a579a06c47cd2ceed95"><gtr:id>a8b607e59f237a579a06c47cd2ceed95</gtr:id><gtr:otherNames>Chaudhri OB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0066-4278</gtr:issn><gtr:outcomeId>3AFB9249407</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701371</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>160D22D0-5677-4513-A0AC-7F3526B7F336</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Metabolic and Endocrine</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>